Monitor for follow-up disclosures or peer-reviewed publications detailing the magnitude and statistical significance of the Phase 2 ALXN1840 results, which could inform the drug's probability of advancing to Phase 3. Without concrete efficacy or safety data in this filing, the stock impact is likely muted and event-driven.
Price Chart
Executive Summary
Monopar Therapeutics presented Phase 2 study results for ALXN1840 (tiomolibdate choline) in Wilson disease at the EASL International Liver Congress 2026. The presentation was disclosed via an 8-K under Item 7.01 (Regulation FD Disclosure) and furnished as Exhibit 99.1, which is an image-based file without extractable quantitative clinical data. This is a routine disclosure of a scientific presentation at a medical conference, not a definitive regulatory or financial milestone.
Key Facts
- Phase 2 study (NCT04422431) results for ALXN1840 in Wilson disease were presented at EASL 2026
- Presentation disclosed via 8-K Item 7.01 on May 29, 2026
- Exhibit 99.1 is an image-based presentation without extractable quantitative endpoints
- No financial guidance, revenue data, or capital allocation changes were included
- ALXN1840 was originally developed by Alexion/AstraZeneca; Monopar's current rights or development path are not described
Financial Impact
No financial figures were disclosed in the filing
Risk Factors
- Phase 2 results may not meet efficacy thresholds for advancement to Phase 3
- Wilson disease is a niche indication with limited commercial upside
- Monopar's rights to ALXN1840 and development timeline remain unclear from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-018896 |
| Document: 0001437749-26-018896-index-headers.html | 0001437749-26-018896 |
| Document: 0001437749-26-018896-index.html | 0001437749-26-018896 |
| Document: 0001437749-26-018896.txt | 0001437749-26-018896 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Institutional Cluster | $72.00 | awaiting T+60 | awaiting T+60 | $71.84 (−0.22%) |
Oct 27, 2026 today | SC 13G | $72.00 | awaiting T+60 | awaiting T+60 | $71.84 (−0.22%) |
Oct 5, 2026 22d ago | Insider Cluster | $79.57 | awaiting T+60 | awaiting T+60 | $71.84 (+9.71%) |
Oct 1, 2026 26d ago | 144 | $77.97 | awaiting T+60 | awaiting T+60 | $71.84 (−7.86%) |
Aug 28, 2026 8w ago | Insider Cluster | $111.93 | awaiting T+60 | awaiting T+60 | $71.84 (−35.82%) |
Aug 27, 2026 8w ago | Insider Cluster | $111.89 | awaiting T+60 | awaiting T+60 | $71.84 (−35.79%) |
Aug 25, 2026 9w ago | 144 | $113.72 | awaiting T+60 | awaiting T+60 | $71.84 (−36.83%) |
Aug 12, 2026 10w ago | 8-K | $114.90 | awaiting T+60 | awaiting T+60 | $71.84 (−37.48%) |
Aug 12, 2026 10w ago | Press Release | $114.90 | awaiting T+60 | awaiting T+60 | $71.84 (−37.48%) |
Jul 22, 2026 13w ago | 8-K | $112.48 $71.80 | ▼ −36.17% | ▼ −39.43% | $71.84 (−36.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers